A large, global Phase 3 registrational trial of BRII-693 in hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP)
Latest Information Update: 29 Mar 2024
At a glance
- Drugs QPX 9003 (Primary)
- Indications Nosocomial pneumonia; Ventilator associated pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Brii Biosciences
Most Recent Events
- 29 Mar 2024 New trial record
- 22 Mar 2024 According to a Brii Biosciences media release, a large, global Phase 3 registrational trial in hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), is expected to begin in 2025.